AG-270
AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM[1].
Product Specifications
CAS Number
[2201056-66-6]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Methionine Adenosyltransferase (MAT)
Type
Reference compound
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ag-270.html
Purity
99.97
Solubility
DMSO : 4 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C(C2=CC=C(OC)C=C2)=C(NC3=NC=CC=C3)NC4=C(C5=CCCCC5)C(C6=CC=CC=C6)=NN14
Molecular Formula
C30H27N5O2
Molecular Weight
489.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Zenon Konteatis, et al. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 8.|[2]Marc L Hyer, et al. The MAT2A inhibitor AG-270 combines with both taxanes and gemcitabine to yield enhanced antitumor activity in patient-derived xenograft models.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
